8
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T0078 | Lapatinib | GSK572016,GW572016 | EGFR , Ferroptosis , Autophagy |
Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression. | |||
T0078L | Lapatinib ditosylate monohydrate | Lapatinib ditosylate monohydrate,Lapatinib ditoluenesulfonate monohydrate,Lapatinib tosilate hydrate,Lapatinib tosilate,Tykerb,Tyverb | EGFR , Ferroptosis , Autophagy |
Lapatinib ditosylate (Lapatinib tosilate) monohydrate is a tyrosine kinase receptor inhibitor used in the therapy of advanced breast cancer and other solid tumors. Lapatinib ditosylate monohydrate therapy is associated w... | |||
T6235 | Lapatinib Ditosylate | Lapatinib (GW-572016) Ditosylate,GW-572016 ditosylate,Tykerb ditosylate | EGFR , Ferroptosis , Autophagy |
Lapatinib Ditosylate (Tykerb ditosylate) is an effective EGFR and ErbB2 inhibitor (IC50: 10.8/9.2 nM for EGFR/ErbB2). | |||
T0077 | Dantrolene sodium | Lapatinib ditosylate monohydrate,Dantrolene sodium salt | Others , Calcium Channel |
Dantrolene sodium (Lapatinib ditosylate monohydrate) salt is a skeletal muscle relaxant and can interfere with excitation-contraction coupling in the muscle fiber. It is used for the treatment of spasticity and other neu... | |||
T72577 | Lapatinib tosylate | GW2016 tosylate,GW572016 tosylate,GW572016 tosylate ; GW2016 tosylate | |
Lapatinib tosylate (GW572016), a robust and orally administered inhibitor specifically targeting the tyrosine kinase domains of ErbB-2 and EGFR, exhibits inhibitory concentration 50 (IC50) values of 10.2 nM and 9.8 nM ag... | |||
T6092 | Sapitinib | AZD-8931 | EGFR |
Sapitinib (AZD-8931) , a reversible, ATP competitive inhibitor of EGFR(IC50=4 nM), ErbB2(IC50=3 nM) and ErbB3(IC50=4 nM), is more effective over Gefitinib or Lapatinib against NSCLC cell, 100-fold more specific for the E... | |||
T36244 | SJF 1521 | ||
Selective EGFR Degrader. Comprises the EGFR inhibitor lapatinib (Cat. No. 6811) joined by a linker to a von Hippel-Lindau (VHL) recruiting ligand. Exhibits selectivity for EGFR, including mutant forms, over HER2. Induces... | |||
T36245 | SJF 1528 | ||
Potent EGFR Degrader (DC50 values are 39.2 nM for wild-type EGFR in OVCAR8 cells and 736 nM for Exon20Ins mutated EGFR in HeLa cells). Also degrades HER2. Comprises the EGFR inhibitor lapatinib (Cat. No. 6811) joined by ... |